REG - OptiBiotix Health - Director's dealing

OptiBiotix HealthAnnouncement

12/07/2018 07:05

RNS Number : 3706U
OptiBiotix Health PLC
12 July 2018
 


OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Director's dealing
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care was notified on 11 July 2018 that Neil Davidson, Non-Executive Chairman of the Company, acquired 210,000 ordinary shares in the Company on 11 July 2018, representing 0.25% of the Company's issued share capital, at a price of 71 pence per share.
 
Previously to this notification, Mr Davidson held 165,000 ordinary shares in the Company. Therefore Neil Davidson's total shareholding represents 0.44% of the Company's issued share capital.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP


Tel: 020 7213 0880




Liam Murray / Jo Turner


















finnCap (Broker)


Tel: 020 7220 0500




Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)








Abigail Wayne (Corporate Broking)


















Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001









 
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
 
 



Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014




1


Details of the person discharging managerial responsibilities/person closely associated




a.


Name


Neil Davidson




2


Reason for notification








a.


Position/Status


Non-Executive Chairman




b.


Initial notification/
Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.


Name


OptiBiotix Health plc




b.


LEI


213800UKYQFT941QHS14




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.


Description of the financial instrument, type of instrument



Identification Code




Ordinary shares



 
ISIN: GB00BP0RTP38




b.


Nature of the transaction


 Purchase of ordinary shares




c.


Price(s) and volume(s)




























Price(s) per share


Volume(s)








 
71 pence


 
210,000








 
 




d.


Aggregated information
 
- Aggregated Volume
 
- Price


 
 
210,000
 
71 pence




e.


Date of the transaction


11 July 2018




f.


Place of the transaction


AIM



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQFLFFVDFBBBD